The effects of exogenous glucagon-like peptide-1 administration on glucose metabolism and gastric emptying in critically ill patients.

Double-blind randomised placebo cross-over trial of exogenous glucagon-like peptide-1 to establish the effect on glucose metabolism and gastric emptying during gastric feeding in critically ill patients

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000562370

Enrollment

Registered

2008-11-07

Start date

2008-11-04

Completion date

2009-07-27

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Adequate nutrition is important to allow patients in the Intensive Care Unit the best chance to recover from their illness. The most common method of feeding patients is through a tube into the gut. However, due to their illness many of these patients have very high levels of glucose (sugar) in the bloodstream, which can have a negative effect on their recovery. The purpose of this study is to determine whether a naturally occurring hormone, called Glucagon-like Peptide-1 (GLP-1), can help lower blood glucose levels and improve the outcome of patients in Intensive Care. GLP-1 is a gastrointestinal hormone that is normally released into the bloodstream in response to a meal.

Interventions

Intravenous Glucagon-like peptide-1 (reconstituted in 4%albumin) at 1.2pmol/kg/min will be administered for 360minutes at 1ml/min. Seperated by 24 hours the cross-over treatment is placebo (intravenous 4% Albumin at 1ml/min for 360minutes

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

17 Years to 90 Years

Healthy volunteers

Inclusion criteria

critically ill patients and mechanically ventilated suitable for, or receiving, enteral nutrition and likely to stay ventilated for at least 48 hours.

Exclusion criteria

Pregnancy, Contraindication to enteral nutrient administration, Previous surgery on the oesophagus, stomach or duodenum, Any gastrointestinal surgery on this hospital admission and History of diabetes mellitus

Outcome results